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Introduction
Graves’ orbitopathy, despite of the results of recent
researches concerning pathomechanism of the disease, is
still a therapeutic challenge. Corticosteroids are the
treatment of choice for active, moderate to severe
Graves’ orbitopathy.
The aim of the study is to evaluate the effects of treat-
ment of patients with GO with novel protocol of steroi-
dotherapy designed and introduced in Department of
Endocrinology, Metabolism and Internal Medicine. The
management protocol consists of 3 g of methylpredniso-
lone administered intravenously followed with methyl-
prednisolone injected intramuscularly in divided doses
every 3 weeks (total dose of methylprednisolone is 3.6 g).
Material and methods
The study group consisted of 50 patients. Assessment of
efficacy of therapy was performed before and immediately
after the therapy and 6 months later. Thyroid function
parameters (TSH, FT4, FT3), titers of thyroid autoantibo-
dies (TRAb, TPOAb, TgAb), thyroid volume (V) were ana-
lyzed. Moreover, ophthalmological findings (soft tissue
involvement, proptosis, diplopia, clinical activity score,
visual acuity) and disease activity on magnetic resonance
imaging of orbits were evaluated.
Results
The therapy significantly improved the degree of soft tis-
sue involvement, CAS, diplopia and decreased the autoim-
mune disease activity in oculomotor muscles. Moreover,
significant decrease of TRAb titer was observed.
Conclusions
To conclude, novel protocol of glucocorticoid therapy is
effective and safe.
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